Experience

Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement

November 18, 2024

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Read more

Related contacts

Mark Ballantyne
Partner, Reston
Kenneth Krisko
Partner, Reston
J. Brian Stalter
Special Counsel, New York
Ruomu Li
Partner, Shanghai
David Brinton
Associate, Washington, DC
Arjan Ganji
Associate, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Daniel I. Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Francis Wheeler
Senior Counsel, Colorado
Rebecca Ross
Special Counsel, Washington, DC
John Forrest
Associate, Boston
Zack Gong
Associate, Shanghai
Michael Shen
Special Counsel, Shanghai
Robin K. Lee
Paralegal Specialist, Colorado

Related Practices & Industries

Admissions and credentials

District of Columbia

Memberships and affiliations

American Bar Association (ABA)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.